PlainPharmaWatch

CMS Open Payments · Tool

TearLab Corp vs Daiichi Sankyo Europe GmbH

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Daiichi Sankyo Europe GmbH has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 2,769, versus 1,113 for the other company. Its single largest recorded recipient represents 42.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

TearLab Corp
HHI 1,113 · top recipient 25.7%
Ranked #987 of 1,838 companies by HHI
Daiichi Sankyo Europe GmbH
HHI 2,769 · top recipient 42.1%
Ranked #602 of 1,838 companies by HHI

Payment Overview

Company A

TearLab Corp

Total Payments
$77.8K
% of Industry
0.0%
Transactions
325
Avg per Transaction
$239.38
Recipients
325
Avg per Recipient
$239.38
Payment Types
6
Top Payment Type
Consulting Fee
Total Payments
$77.3K
% of Industry
0.0%
Transactions
33
Avg per Transaction
$2.3K
Recipients
33
Avg per Recipient
$2.3K
Payment Types
4
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

TearLab Corp vs Daiichi Sankyo Europe GmbH - total reported payments in CMS Open Payments PY2024

TearLab Corp$77.8KDaiichi Sankyo Europe GmbH$77.3K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

TearLab Corp

Consulting Fee $32.3K

41.5%

Honoraria $20.0K

25.7%

Gift $10.4K

13.3%

Food and Beverage $8.8K

11.3%

Compensation for Faculty or Speaker (Medical Education) $6.3K

8.1%

Travel and Lodging $19.17

0.0%

Daiichi Sankyo Europe GmbH

Consulting Fee $45.2K

58.4%

Travel and Lodging $30.8K

39.9%

Education $652.73

0.8%

Food and Beverage $611.42

0.8%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

TearLab Corp

  1. 1

    RICHARD LINDSTROM

    $20,000.00 · 2 txns

  2. 2

    LISA NIJM

    $11,447.34 · 4 txns

  3. 3

    ERIC DONNENFELD

    $10,000.00 · 1 txns

  4. 4

    KENNETH BECKMAN

    $2,100.00 · 2 txns

  5. 5

    DAMON DIERKER

    $2,000.00 · 1 txns

Daiichi Sankyo Europe GmbH

  1. 1

    ROBERT P GIUGLIANO

    $32,517.52 · 13 txns

  2. 2

    SUNG HEE LESLIE CHO

    $20,204.74 · 10 txns

  3. 3

    SHANU MODI

    $12,360.30 · 4 txns

  4. 4

    EDWARD JEFFREY BLOCH

    $3,750.00 · 1 txns

  5. 5

    HARRY ERBA

    $3,256.70 · 1 txns

Summary Comparison

Metric TearLab Corp Daiichi Sankyo Europe GmbH
Total Payments $77.8K $77.3K
% of Industry Total 0.0% 0.0%
Transaction Count 325 33
Avg per Transaction $239.38 $2.3K
Recipient Count 325 33
Avg per Recipient $239.38 $2.3K
Payment Type Count 6 4
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.